Tongrentang is blacklisted six times a year. Why are old brands mired in quality quagmire?

I just saw a piece of news today. It was reported by the media that Beijing Tongrentang was on the blacklist of quality inspection six times a year, involving unqualified sampling results of related products produced and the sale of inferior drugs. I used to know something about it. Generally speaking, Tongrentang cut corners on many Chinese herbal medicines, and the composition and content of some drugs do not meet the national standards. In fact, when such a thing was exposed before entering the house, it caused people's controversy, because this old brand focused on the word "old", and it was hard for people to imagine that the old brand we used would have such a serious problem.

But what did we see after that? Not to strengthen strict quality control, not to strengthen the protection of medicinal materials and technology, but like a bird that has lost its flying heart. Even if it has wings, it is only willing to get stuck in the mire and refuse to try to fly. In this year, why didn't Tongrentang make any corrections when it first broke the quality problem? The first time I was "honored" on the black list for six times. Looking at the old brands in China, it is the first time to see such "error correction", so this is not the quality problem of the old brands. In my opinion, this is just a problem of Tong Ren Tang.

Why does Tong Ren Tang keep covering up the facts without taking measures?

On February 18, Tongrentang stated in the clarification announcement that "Tongrentang (Bozhou) Pieces Company is a Chinese herbal pieces production enterprise controlled by Beijing Tongrentang Medicinal Materials Ginseng Investment Group Co., Ltd., Beijing Tongrentang (Group) Co., Ltd. (hereinafter referred to as Tongrentang Group). The media pay attention to the fact that "Radix Glycyrrhizae Preparata", "Rhizoma Drynariae", "Radix Rehmanniae Preparata" and "Potentilla discolor" are all produced and sold by Tongrentang (Bozhou) Pieces Company, not our products. The company has not produced such pieces. " This announcement means that Tongrentang does not admit that it was produced by the parent company, but by the subsidiary of the parent company under the banner of colleagues. I think this statement is irresponsible.

From the perspective of the parent company, this subsidiary has an independent legal representative, so it cannot be called a branch. From a legal point of view, in fact, the parent company does not have so many controlling shares in its subsidiaries. In some aspects, a subsidiary, as an independent legal person, is responsible for its operating liabilities to the extent of its own property. Simply think that it can be said that the parent company has the right to be unnecessarily responsible for the production of what happens to its subsidiaries. However, today's subsidiaries generally do not inherit the management of enterprises like branches. The most common thing is that small companies sell shares to become subsidiaries in the case of poor management. However, the parent company has strict inspection requirements when determining whether it agrees to become a subsidiary. From this perspective, the irregular regular inspection of the parent company will lead to such a thing.

2065438+In February, 2006, the US Food and Drug Administration of Shandong Province issued the Announcement of Drug Quality in Shandong Province, and Weifang Shouguang Kang Hua Pharmaceutical Chain Co., Ltd. was notified for selling Potentilla discolor with unqualified characters.

2065438+August 2006, Sichuan Province sampled 7 batches of non-essential drugs produced by Gulin County Hospital of Traditional Chinese Medicine? "Jiawei Zuojin Pill" has a "black list" of product loading differences.

20 16 10 The website of the US Food and Drug Administration in Zibo released the Statistical Report on Information Disclosure of Food and Drug Administrative Punishment Cases in Zibo (September), and all the enterprises and individuals involved were punished for food and drug safety problems, including the case of Beijing Tongrentang Zibo Pharmacy Co., Ltd. selling inferior drugs.

20 16, 10, Hubei American food and drug administration announced 16 the results of drug supervision and sampling inspection in the second quarter, among which Beijing Tongrentang (Bozhou) Pieces Co., Ltd. was blacklisted again.

20 16 12, official website, Guizhou American food and drug administration, issued the "20 16 announcement on the second phase of drug inspection in Guizhou province" to announce to the public the unqualified drugs sampled in Guizhou province, including Jingtongrentang? Rhizoma Drynariae produced by Bozhou Pieces Co., Ltd. and ear nail capsules produced by Tonghua Jinma Pharmaceutical Co., Ltd.

20 17 February, official website and Tianjin Municipal Market and Quality Supervision and Management Committee announced the sampling results of drug quality supervision in the second half of 20 16. Among them, Beijing Tongrentang (Bozhou) Pieces Co., Ltd. was blacklisted again because the content of roasted licorice was unqualified.

Judging from these dazzling facts, the parent company still didn't take any improvement measures after the February incident of 16, and even relied on such lame excuses and reasons as "this formula is not our company" every time.

Why is this?

We carefully observe the rise and fall of Tongrentang's stock market. Tongrentang's stock market has been falling because people are beginning to be disappointed with Tongrentang. In fact, the year of 2000 should be regarded as the golden age of Tongrentang, and it should be the best opportunity to consolidate the company. However, at this stage, Tongrentang constantly acquired subsidiaries and expanded its "development", which laid a curse for the current situation.

Is there any other reason besides this?

Shi Lichen, head of Beijing Chen Ding Medicine Management Consulting Center, told the Securities Daily reporter that "Chinese herbal pieces are an important part of the Chinese medicine industry chain, but in recent years, Chinese herbal pieces have been repeatedly exposed to quality problems. The quality crisis of well-known enterprises reflects the problems faced by the entire Chinese medicine industry. " ?

From this point of view, the industrial chain of this Chinese medicine industry is still in great crisis, and a considerable part of this problem still appears in the raw materials of Chinese medicine. According to insiders, most insiders know that there are very big problems in the direction of raw materials. First-class medicinal materials are used for export, and second-class medicinal materials flow into large hospitals. Those unqualified and inferior third-rate medicinal materials, even some of them are dregs, have been made into various Chinese patent medicines, which is also the reason why the quality problems of traditional Chinese medicine appear so frequently. Cai said in an interview with reporters: "If we follow the standards, the cost will be high."

Does this affect the raw materials of traditional Chinese medicine? I think there are other reasons, such as the pollution of traditional Chinese medicine raw materials caused by environmental degradation, or the gradual loss of technology when people operate, and I think the most important thing is that the supervision of raw material production is too weak, and it can even be said that officials protect each other, resulting in a growing gap in raw materials for traditional Chinese medicine.

Then why are all the good raw materials exported and the dregs made into Chinese patent medicine for our own people to take?

This is precisely because the domestic supervision is not enough, because the supervision of pharmaceutical raw materials abroad is very strict. If it is not good material, it is impossible to enter the foreign medical system. China can be said to be fishing in troubled waters. Therefore, of course, manufacturers choose to export good raw materials. Domestic manufacturing does not care about quality, and it is also reducing the cost of drugs. In a profiteering industry like China, such high profits have certainly won the love of various pharmaceutical companies, which has gradually evolved into the present.